TIF.ACCESS Project
The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both the Zynteglo Gene Therapy by the European Medicines Agency (EMA) and the Reblozyl drug by both the EMA and the US Food and Drug Administration (FDA) for patients with transfusion-dependent β-thalassaemia (TDT).
As the accessibility of these therapies relies heavily on the initiation of an early dialogue between the industry, governments and patients, TIF has decided to launch the TIF.ACCESS series of fora, in order to inform and educate patient groups, healthcare professionals, national health authorities, reimbursement agencies and other involved stakeholders on the rights of patients with haemoglobin disorders across the world for prompt and equal access to every existing and future therapy.
TIF.ACCESS is a necessary breakthrough to find solutions to the global problem of access to novel therapies and hold discussions around related topics, such as their affordability, pricing models, added-value, public health, long-term cost effectiveness.
TIF.ACCESS is an acronym for “TIF’s International Forum on ACCessibility, Effectiveness and Sustainability of TherapieS for Haemoglobin Disorders”.
TIF.ACCESS Programme: Guidance & Best Practices for Patient Associations
